| HOME >> MEDICINE >> TECHNOLOGY |
2.11 Methods of Vaccine Production
2.11.1 Egg-Based Manufacturing Technology
2.11.2 Cell-Based Manufacturing Technology
2.11.2.1 MCDK (Madin Darby Canine Kidney Cells)
2.11.2.2 Vero Cells
2.11.2.3 Per C6 Cells
2.11.3 Cell-Based Technique has an Edge over Egg-Based Vaccine Production
2.11.4 Steps Involved in Vaccine Production
2.11.5 Distribution of Vaccine
2.12 Influenza Pandemics - The New Threat
2.12.1 Increasing Global Vaccine Access to Combat Pandemic Influenza
2.12.2 Government Policy Regarding Pandemic Influenza Vaccines in the Mature Markets
3. The Influenza Vaccine Market - Global, Mature and Emerging
3.1 Challenges of the Global Influenza Vaccine Market
3.2 The Global Influenza Market Worth $4.3bn in 2009
3.3 The Global Market Projected to Grow to 2021
3.4 The Mature Market Projected to Maintain Steady Growth
3.5 The Emerging & Other Markets Projected to Expand Rapidly
3.6 The Growth Rate of the Emerging & Other Market Category Projected to be the Highest
4. Analysis of the Leading Players in the Influenza Vaccines Market
4.1 Influenza Vaccine Sales Estimate for Sanofi Pasteur
4.1.1 Fluzone/Vaxigrip
4.1.2 Investing in Building Capacity
4.2 Novartis Influenza Vaccines Sales to 2021
4.2.1 Fluvirin
4.3 GlaxoSmithKline PLC
4.3.1 GSK's Acquisition of ID Biomedical
4.3.2 Fluviral/FluLaval
4.3.3 Fluarix
4.3.4 Key Contracts Announced by GSK to Date
4.4 Other Manufacturers in the Mature Markets
4.4.1 Sales Forecasts for Influvac, Flumist and Inflexal
4.5 The Top Players are Building Global Manufacturing Capacities
4.6 The Key Players are Increasing Manufacturing Capacity in the Emerging Markets
5. Analysis of Mature Markets - the US, Japan, Germany,
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |